A new CVS Caremark settlement caps insulin costs and sets up a deductible change for TrumpRx purchases. Here's what's in the ...
Federal regulators say a new settlement with one of the country’s largest pharmacy benefit managers could lead to lower prescription drug costs.
A rebate-driven formulary model allegedly incentivized higher insulin list prices, affecting three PBMs controlling roughly ...
The FTC settled a lawsuit against CVS Caremark over allegations that the company artificially inflated the price of insulin and impeded access to the diabetes treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results